Published April 6, 2026 | Version v1
Journal article Open

Natural flavonoids as prospective inhibitors of human cholinesterase enzymes evaluated through molecular docking

Authors/Creators

  • 1. Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Medical University of Varna, Varna, Bulgaria
  • 2. Department of Biology, Faculty of Pharmacy, Medical University of Varna, Varna, Bulgaria

Description

Alzheimer's disease (AD) represents the most prevalent form of dementia, with acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitors constituting first-line symptomatic treatment. This study evaluates the inhibitory potential of ten naturally occurring flavonoids—apigenin, chrysin, fisetin, galangin, isorhamnetin, kaempferol, luteolin, myricetin, naringenin, and quercetin—against human AChE and BChE through molecular docking simulations. Results demonstrate that fisetin (FIS), luteolin (LUT), and apigenin (API) exhibit the highest affinity for AChE (lowest ΔG and Ki), consistent with their planarity and moderate polarity. For BChE, myricetin (MYR) forms the most stable complex, followed by FIS and LUT, as the wider and more polar active pocket favors highly hydroxylated flavonols. Isorhamnetin (IHN) shows the weakest affinity due to reduced donor–acceptor capacity from 3'-O-methylation. FIS and LUT emerge as dual-target candidates, whereas MYR demonstrates BChE selectivity. These findings identify promising natural scaffolds for developing safer cholinesterase inhibitors with potential therapeutic applications in neurodegenerative diseases, warranting further in vitro and in vivo validation.

Files

PHAR_article_187304.pdf

Files (1.3 MB)

Name Size Download all
md5:195c1ddb5b06c5d23b5128c4c98037ed
1.2 MB Preview Download
md5:6903bb742af610191e3fffea097fed44
95.3 kB Preview Download

Additional details

Cites
Publication: 10.1093/nar/28.1.235 (DOI)
Publication: 10.3934/Neuroscience.2021005 (DOI)
Publication: 10.3390/ijms232314835 (DOI)
Publication: 10.1021/jm300871x (DOI)
Publication: 10.3390/nu17010078 (DOI)
Publication: 10.2174/1570159X11311030006 (DOI)
Publication: 10.1155/2013/645086 (DOI)
Publication: 10.2174/1570159X13666150716165726 (DOI)
Publication: 10.1186/1758-2946-4-17 (DOI)
Publication: 10.3390/nu15071579 (DOI)
Publication: 10.1038/nrd1549 (DOI)
Publication: 10.1038/s41582-024-00940-4 (DOI)
Publication: 10.1038/srep39495 (DOI)
Publication: 10.3390/brainsci15050485 (DOI)
Publication: 10.1155/2013/162750 (DOI)
Publication: 10.1017/S1461145705005833 (DOI)
Publication: 10.1016/j.fbio.2022.102312 (DOI)
Publication: 10.2174/1568026614666140929124445 (DOI)
Publication: 10.1002/jcc.21256 (DOI)
Publication: 10.1016/j.phymed.2007.02.002 (DOI)
Publication: 10.3389/fnagi.2022.996030 (DOI)
Publication: 10.21873/invivo.13822 (DOI)
Publication: 10.2174/1570159X18666201119153807 (DOI)
Publication: 10.18311/jnr/2025/48378 (DOI)
Publication: 10.1107/S2059798324006776 (DOI)
Publication: 10.1016/j.crstbi.2024.100146 (DOI)
Publication: 10.1016/S0140-6736(20)32205-4 (DOI)
Publication: 10.3390/medicines5030093 (DOI)
Has part
Figure: 10.3897/pharmacia.73.e187304.figure3 (DOI)
Figure: 10.3897/pharmacia.73.e187304.figure2 (DOI)
Figure: 10.3897/pharmacia.73.e187304.figure1 (DOI)

References

  • Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) The Protein Data Bank. Nucleic Acids Research 28(1): 235–242. https://doi.org/10.1093/nar/28.1.235
  • Calabrò M, Rinaldi C, Santoro G, Crisafulli C (2020) The biological pathways of Alzheimer disease: a review. AIMS Neuroscience 8(1): 86–132. https://doi.org/10.3934/Neuroscience.2021005
  • Calderaro A, Patanè GT, Tellone E, Barreca D, Ficarra S, Misiti F, Laganà G (2022) The neuroprotective potentiality of flavonoids on Alzheimer's disease. International Journal of Molecular Sciences 23(23): 14835. https://doi.org/10.3390/ijms232314835
  • Cheung J, Rudolph MJ, Burshteyn F, Cassidy MS, Gary EN, Love J, Franklin MC, Height JJ (2012) Structures of human acetylcholinesterase in complex with pharmacologically important ligands. Journal of Medicinal Chemistry 55(22): 10282–10286. https://doi.org/10.1021/jm300871x
  • Cichoń N, Grabowska W, Górniak L, Stela M, Harmata P, Ceremuga M, Bijak M (2025) Mechanistic and therapeutic insights into flavonoid-based inhibition of acetylcholinesterase: Implications for neurodegenerative diseases. Nutrients 17(1): 78. https://doi.org/10.3390/nu17010078
  • Colovic MB, Krstić DZ, Lazarević-Pašti TD, Bondžić AM, Vasić VM (2013) Acetylcholinesterase inhibitors: Pharmacology and toxicology. Current Neuropharmacology 11(3): 315–335. https://doi.org/10.2174/1570159X11311030006
  • Ding X, Ouyang MA, Liu X, Wang RZ (2013) Acetylcholinesterase inhibitory activities of flavonoids from the leaves of Ginkgo biloba against brown planthopper. Journal of Chemistry 2013: 645086. https://doi.org/10.1155/2013/645086
  • Ferreira-Vieira TH, Guimarães IM, Silva FR, Ribeiro FM (2016) Alzheimer's disease: Targeting the cholinergic system. Current Neuropharmacology 14(1): 101–115. https://doi.org/10.2174/1570159X13666150716165726
  • Hanwell MD, Curtis DE, Lonie DC, Vandermeersch T, Zurek E, Hutchison GR (2012) Avogadro: An advanced semantic chemical editor, visualization, and analysis platform. Journal of Cheminformatics 4(1): 17. https://doi.org/10.1186/1758-2946-4-17
  • Jamal QMS, Khan MI, Alharbi AH, Ahmad V, Yadav BS (2023) Identification of natural compounds of the apple as inhibitors against cholinesterase for the treatment of Alzheimer's disease: An in silico molecular docking simulation and ADMET study. Nutrients 15(7): 1579. https://doi.org/10.3390/nu15071579
  • Kitchen DB, Decornez H, Furr JR, Bajorath J (2004) Docking and scoring in virtual screening for drug discovery: Methods and applications. Nature Reviews Drug Discovery 3(11): 935–949. https://doi.org/10.1038/nrd1549
  • Korczyn AD, Grinberg LT (2024) Is Alzheimer disease a disease? Nature Reviews Neurology 20(4): 245–251. https://doi.org/10.1038/s41582-024-00940-4
  • Košak U, Brus B, Knez D, Šink R, Žakelj S, Trontelj J, Pišlar A, Šlenc J, Gobec M, Živin M, Tratnjek L, Perše M, Sałat K, Podkowa A, Filipek B, Nachon F, Brazzolotto X, Więckowska A, Malawska B, Stojan J, Raščan IM, Kos J, Coquelle N, Colletier JP, Gobec S (2016) Development of an in vivo active reversible butyrylcholinesterase inhibitor. Scientific Reports 6: 39495. https://doi.org/10.1038/srep39495
  • Kruszka J, Martyński J, Szewczyk-Golec K, Woźniak A, Nuszkiewicz J (2025) The role of selected flavonoids in modulating neuroinflammation in Alzheimer's disease: Mechanisms and therapeutic potential. Brain Sciences 15(5): 485. https://doi.org/10.3390/brainsci15050485
  • Kumar S, Pandey AK (2013) Chemistry and biological activities of flavonoids: An overview. The Scientific World Journal 2013: 162750. https://doi.org/10.1155/2013/162750
  • Lane RM, Potkin SG, Enz A (2006) Targeting acetylcholinesterase and butyrylcholinesterase in dementia. International Journal of Neuropsychopharmacology 9(1): 101–124. https://doi.org/10.1017/S1461145705005833
  • Li N, Yang J, Wang C, Wu L, Liu Y (2023) Screening bifunctional flavonoids with anti-cholinesterase and anti-glucosidase activities by in vitro and in silico studies: Quercetin, kaempferol and myricetin. Food Bioscience 51: 102312. https://doi.org/10.1016/j.fbio.2022.102312
  • Lionta E, Spyrou G, Vassilatis DK, Cournia Z (2014) Structure-based virtual screening for drug discovery: Principles, applications and recent advances. Current Topics in Medicinal Chemistry 14(16): 1923–1938. https://doi.org/10.2174/1568026614666140929124445
  • Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ (2009) AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry 30(16): 2785–2791. https://doi.org/10.1002/jcc.21256
  • Mukherjee PK, Kumar V, Mal M, Houghton PJ (2007) Acetylcholinesterase inhibitors from plants. Phytomedicine 14(4): 289–300. https://doi.org/10.1016/j.phymed.2007.02.002
  • Murakami S, Lacayo P (2022) Biological and disease hallmarks of Alzheimer's disease defined by Alzheimer's disease genes. Frontiers in Aging Neuroscience 14: 996030. https://doi.org/10.3389/fnagi.2022.996030
  • Negru DC, Bungau SG, Radu A, Tit DM, Radu AF, Nistor-Cseppento DC, Negru PA (2025) Evaluation of the alkaloids as inhibitors of human acetylcholinesterase by molecular docking and ADME prediction. In Vivo 39(1): 236–250. https://doi.org/10.21873/invivo.13822
  • Orhan IE (2021) Cholinesterase inhibitory potential of quercetin towards Alzheimer's disease – a promising natural molecule or fashion of the day? – A narrowed review. Current Neuropharmacology 19(12): 2205–2213. https://doi.org/10.2174/1570159X18666201119153807
  • Parmar P, Patel PH (2025) In silico insights into marine natural products as AChE and BChE inhibitors. Journal of Natural Remedies 25(9): 2137–2148. https://doi.org/10.18311/jnr/2025/48378
  • Read RJ, Pettersen EF, McCoy AJ, Croll TI, Terwilliger TC, Poon BK, Meng EC, Liebschner D, Adams PD (2024) Likelihood-based interactive local docking into cryo-EM maps in ChimeraX. Acta Crystallographica D: Structural Biology 80: 588–598. https://doi.org/10.1107/S2059798324006776
  • Sadeghi M, Seyedebrahimi S, Ghanadian M, Miroliaei M (2024) Identification of cholinesterase inhibitors from flavonoid derivatives for possible treatment of Alzheimer's disease: In silico and in vitro approaches. Current Research in Structural Biology 7: 100146. https://doi.org/10.1016/j.crstbi.2024.100146
  • Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, Cummings J, van der Flier WM (2021) Alzheimer's disease. The Lancet 397(10284): 1577–1590. https://doi.org/10.1016/S0140-6736(20)32205-4
  • Skender-Gazibara M, Slobodan (2001) Neuropathological hallmarks of Alzheimer's disease. Archives of Oncology 9(1): 5–7.
  • Tungmunnithum D, Thongboonyou A, Pholboon A, Yangsabai A (2018) Flavonoids and other phenolic compounds from medicinal plants for pharmaceutical and medical aspects: An overview. Medicines 5(3): 93. https://doi.org/10.3390/medicines5030093